… and challenges of AD drug development. We focus on development of DMTs for individuals
with early disease, which may be more amenable to disease modification and most likely to …

… in preclinical and clinical development [11]. … treatment development in AD. It is the second
most popular class in both clinical development (13%, 20 drugs) and preclinical development (…

… treatments for Alzheimer's disease (AD) fail to address the underlying pathology of the disease…
to AD, as well as in biomarker development, have brought with them the promise of earlier …

… and potential pitfalls in diagnosis, choice of therapeutic targets, development of drug … cure
for Alzheimer's disease is unlikely to be found and that the approach to drug development for …

… Passive immunotherapy remains the leading approach to disease-modifying treatment…
Alzheimer Disease Cooperative Study (ADCS). Solanezumab was noted to be safe, but treatment …

… Treatments for Alzheimer's disease (AD) are needed due to the growing number of individuals
… Drug development for AD therapies can be examined by inspecting the drug development …

… We kept the terminology of “symptomatic” treatments for agents whose purpose was … death
in AD, and we used “disease-modifying” for treatments intended to change the biology of AD …

… Alzheimer's disease (AD) has few available treatments, and there is a high rate of failure
in AD drug development … Drug discovery and development for Alzheimer's disease (AD) is …

… develop new treatments for Alzheimer's disease (AD) and to understand the drug development
… the current drug development approaches for AD treatments, we examined the AD drug …

… Alzheimer's disease (AD) is rapidly becoming a major public health threat with increasing
numbers of affected individuals as the world's population ages. There are currently 5.3 million …